Filtrar

Publicações

A Budget Impact Analysis (BIA) of Transcatheter Aortic Valve Implantation (TAVI) in High-Risk Patients with Symptomatic Severe Valve Stenosis (SSVS) Under the Brazilian Public Health Care System (SUS) Perspective

Abstract

Objectives: Aortic valve stenosis is a progressive valvular heart disease with a stand- ard care that involves a major open surgery. However, part of the patients is ineligible for surgery, therefore drug therapy is the only option available. Once TAVI is a less invasive surgical option, clinical trials demonstrated ...

Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis

Abstract

BACKGROUND: This paper reports a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy of lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in human epidermal growth factor receptor 2-overexpressing (HER-2+) locally advanced or metastatic breast cancer. ...

Cost-Effectiveness of Transcatheter Aortic-Valve Implantation for Severe Symptomatic Aortic Stenosis in Inoperable Patients in the Brazilian Private Health Care System

Abstract

Objectives: Aortic stenosis is the most common valvular heart disease in the elderly –its prevalence is estimated to be up to 5% in individuals over 75 years. Surgical replacement of aortic valve is considered the standard care and in the absence of serious coexisting conditions, the procedure is associated with low ...

Transcatheter Pulmonary Valve Implantation: Systematic Literature Review

Abstract

Surgical repair of some complex congenital heart diseases involves reconstruction of the right ventricular outflow tract using homografts, bioprostheses, bovine jugular grafts or other valved conduits between the right ventricle and the main pulmonary artery. Although these surgical procedures may be performed with low ...

Cost-Effectiveness Analyses of Natalizumab for 2nd Line Versus Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients in Brazil

Abstract

Objectives: Multiple sclerosis (MS) is a neurologic disease that can dramatically affect patients. The aim of this study is to conduct a cost-effectiveness analysis of natalizumab (Tysabri®) versus glatiramer acetate (Copaxone®) for treatment of Relapsing Remitting Multiple Sclerosis (RRMS) patients from the Brazilian ...

Indirect comparison between dapagliflozin, sitagliptin and saxagliptin for the treatment of patients with type 2 diabetes mellitus inadequately controlled with metformin

Abstract

Objective: To conduct a systematic review and an indirect comparison meta-analysis to assess whether there are differences between the addition of dapagliflozin to metformin or dipeptidyl dipeptidase-4 inhibitor (sitagliptin and saxagliptin) to metformin in patients with type 2 diabetes mellitus (T2DM) ...

Cost-Utility Analyses of Natalizumab Versus Interferon Beta-1a 44 Mcg for Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RESRRMS) Patients in Brazil

Abstract

Objectives: Multiple sclerosis (MS) is a neurologic disease that can dramatically affect patients’ quality of life. The aim of this study is to conduct a cost-utility analysis of natalizumab (Tysabri®) versus interferon beta-1a 44 mcg (Rebif®) – a commonly prescribed 1st line disease modifying therapy – in rapidly ...

Clinical value of biological therapies in oncology: measurement of outcomes for benefits evaluation

Abstract

Introduction: Oncology represents a major challenge in setting criteria for inclusion of new treatments. The high costs associated with cancer explain the great concern of the healthcare payers with the added value of new cancer treatments. Following the precepts of evidence-based medicine allows the use of best available ...

Natalizumab for 2nd Line Treatment in Relapsing-Remitting Multiple Sclerosis Patients: 5-Year Budget Impact Analysis (BIA) from the Brazilian Public Payer Perspective

Abstract

Objectives: Multiple sclerosis (MS) is a neurodegenerative disease associated with long-term disability and economic impact. With the addition of new agents for the MS treatment (e.g. natalizumab), there is a need to evaluate the relative value of newer therapies in terms of cost, given health care resource constraints ...

Targeted Therapy in Triple-Negative Metastatic Breast Cancer (TNBC) - A Systematic Review and Meta-Analysis

Abstract

Objectives: To perform a systematic review and meta-analysis of all randomized controlled trials comparing the efficacy of targeted therapy to conventional CT in patients with metastatic Triple-Negative Breast Cancer (TNBC). Methods: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The ...